Renaissance Capital logo

CCXI News

TPG-backed biotech Virobay files for a $50 million IPO

Virobay, an early-stage biotech developing a drug platform for pain, Crohn's disease and psoriasis, filed on Wednesday with the SEC to raise up to $50 million in an initial public offering. The company's drug development platform is based on inhibiting cysteine...read more

ChemoCentryx quiet period ends March 19

ChemoCentryx, which is developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo, will see its quiet period end on 3/19/12. On 2/8/12, the company raised $45.0 million by offering 4.5 million shares at $10.00, below the range of $14.00 to...read more

Caesars stands out in a busy pricing week with strong returns

This week saw 8 IPOs completed, the most deals priced since the week of December 12th (which itself was the busiest week of 2011) and the returns left investors happy. Despite significant pricing pressure (only two managed to price at the midpoint; the rest were...read more

ChemoCentryx prices downsized IPO at $10, below the range

ChemoCentryx, a biotech developing novel drugs for Crohn's disease and rheumatoid arthritis, raised $45 million by offering 4.5 million shares at $10, below the range of $14 to $16. The company had originally planned to sell 4 million shares, resulting in a...read more